Gibson Dunn Represents Apogee Therapeutics, Inc. in Upsized Initial Public Offering

July 18, 2023

Gibson, Dunn & Crutcher LLP is advising Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications, on its upsized initial public offering.

The Gibson Dunn corporate team includes San Francisco partners Ryan Murr and Branden Berns and associate Melanie Neary.